Videos

At the ESMO Congress 2025 in Berlin, Dr. Michael Gordon, Chief Medical Officer at the HonorHealth Research Institute, presented updated results from Agenus’ Phase 1b C-800-01 study evaluating botensilimab (BOT) and balstilimab (BAL) in more than 400 patients with advanced refractory solid tumors. Hear him deliver his presentation along with slides from ESMO 2025 Abstract #1517MO).

At the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GI) in San Francisco, Agenus presented new data on its next-generation immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for colorectal cancer. Join Agenus Chief Medical Officer Dr. Steven O’Day as he explores these findings.